$JUPW Jupiter Wellness' to Present JW-300 Topical
Post# of 37073
(Total Views: 144)
Posted On: 06/13/2022 1:50:36 PM
$JUPW Jupiter Wellness' to Present JW-300 Topical Burn Treatment at SCALE 2022 Aesthetic Medicine, Plastic Surgery & Medical Dermatology Conference
JW-300 Demonstrated Efficacy in the Treatment of Developing Burns (sunburn) in a Double-Blinded Placebo-Controlled Clinical Trial
JUPITER, FL / ACCESSWIRE / May 4, 2022/Jupiter Wellness, Inc. (NASDAQ:JUPW) will present data for Jupiter's JW-300, a cannabidiol topical treatment for first degree burns, at SCALE 2022 Aesthetic Medicine, Plastic Surgery & Medical Dermatology Conference to take place May 11-15, 2022 in Nashville, Tennessee.
In a clinical trial of 36 patients, a controlled area of skin was exposed to UV irradiation. The percentage of subjects who experienced burns (measured by erythema) in patients treated with JW-300 was significantly lower (p=0.047) than in subjects who received the placebo lotion. The percent of subjects who were burned in the placebo arm was 61% compared to 27% in patients treated with JW-300. In addition, in patients (n=18) treated with JW-300, the average erythema score was 0.388 after radiation compared to 0.722 in the placebo arm (n=18).
Dr Glynn Wilson, Chief Scientist of Jupiter Wellness, commented, "These statistically significant results demonstrate JW-300's potential as either a prescription or over-the-counter topical cream to help prevent sunburn and its more harmful consequences such as skin cancer. We look forward to presenting these important data to leading dermatology and aesthetic medicine physicians at SCALE."
Jupiter CEO Brian John added, "JW-300 complements our current over-the-counter skincare products including CaniSun™ as well as our prescription product Photocil™, serving a large market that needs more effective solutions."
https://finance.yahoo.com/news/jupiter-wellne...00385.html
JW-300 Demonstrated Efficacy in the Treatment of Developing Burns (sunburn) in a Double-Blinded Placebo-Controlled Clinical Trial
JUPITER, FL / ACCESSWIRE / May 4, 2022/Jupiter Wellness, Inc. (NASDAQ:JUPW) will present data for Jupiter's JW-300, a cannabidiol topical treatment for first degree burns, at SCALE 2022 Aesthetic Medicine, Plastic Surgery & Medical Dermatology Conference to take place May 11-15, 2022 in Nashville, Tennessee.
In a clinical trial of 36 patients, a controlled area of skin was exposed to UV irradiation. The percentage of subjects who experienced burns (measured by erythema) in patients treated with JW-300 was significantly lower (p=0.047) than in subjects who received the placebo lotion. The percent of subjects who were burned in the placebo arm was 61% compared to 27% in patients treated with JW-300. In addition, in patients (n=18) treated with JW-300, the average erythema score was 0.388 after radiation compared to 0.722 in the placebo arm (n=18).
Dr Glynn Wilson, Chief Scientist of Jupiter Wellness, commented, "These statistically significant results demonstrate JW-300's potential as either a prescription or over-the-counter topical cream to help prevent sunburn and its more harmful consequences such as skin cancer. We look forward to presenting these important data to leading dermatology and aesthetic medicine physicians at SCALE."
Jupiter CEO Brian John added, "JW-300 complements our current over-the-counter skincare products including CaniSun™ as well as our prescription product Photocil™, serving a large market that needs more effective solutions."
https://finance.yahoo.com/news/jupiter-wellne...00385.html
(0)
(0)Scroll down for more posts ▼